Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luke Mitcheson

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
BMJ Open|December 4, 2024
Patient experience of opioid use disorder treatment medications: a systematic review of contemporary qualitative researchNatalie Lowry, Carina Najia, Mike Kelleher, et al.
The International Journal on Drug Policy|July 22, 2008
Sexual health risk among dance drug users: cross-sectional comparisons with nationally representative dataLuke Mitcheson, Jim McCambridge, Angela Byrne, et al.
BJU International|March 16, 2012
The prevalence and natural history of urinary symptoms among recreational ketamine usersAdam R Winstock, Luke Mitcheson, David A Gillatt, et al.
Addiction (Abingdon, England)|May 20, 2011
Mephedrone: use, subjective effects and health risksAdam Winstock, Luke Mitcheson, John Ramsey, et al.
Contemporary Clinical Trials Communications|April 27, 2018
Memory-focused cognitive therapy for cocaine use disorder: Rationale, design and protocol for an external pilot randomised controlled trialJohn Marsden, Camille Goetz, Tim Meynen, et al.
Ebiomedicine|February 27, 2018
Memory-Focused Cognitive Therapy for Cocaine Use Disorder: Theory, Procedures and Preliminary Evidence From an External Pilot Randomised Controlled TrialJohn Marsden, Camille Goetz, Tim Meynen, et al.
Addiction (Abingdon, England)|January 31, 2025
Psychedelic-assisted treatment for substance use disorder: A narrative systematic reviewTheodore Piper, Francesca Small, Sam Brown, et al.
BMJ Open|October 21, 2022
Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluationNatalie Lowry, Fiona Cowden, Edward Day, et al.
BMJ Open|March 21, 2023
Patients' perceptions of self-administered dosing to opioid agonist treatment and other changes during the COVID-19 pandemic: a qualitative studyGemma Scott, Sophie Turner, Natalie Lowry, et al.
The Lancet. Psychiatry|April 7, 2019
Efficacy and cost-effectiveness of an adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: a pragmatic, open-label, randomised controlled trialJohn Marsden, Garry Stillwell, Kirsty James, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
BMJ Open|December 4, 2024
Patient experience of opioid use disorder treatment medications: a systematic review of contemporary qualitative researchNatalie Lowry, Carina Najia, Mike Kelleher, et al.
The International Journal on Drug Policy|July 22, 2008
Sexual health risk among dance drug users: cross-sectional comparisons with nationally representative dataLuke Mitcheson, Jim McCambridge, Angela Byrne, et al.
BJU International|March 16, 2012
The prevalence and natural history of urinary symptoms among recreational ketamine usersAdam R Winstock, Luke Mitcheson, David A Gillatt, et al.
Addiction (Abingdon, England)|May 20, 2011
Mephedrone: use, subjective effects and health risksAdam Winstock, Luke Mitcheson, John Ramsey, et al.
Contemporary Clinical Trials Communications|April 27, 2018
Memory-focused cognitive therapy for cocaine use disorder: Rationale, design and protocol for an external pilot randomised controlled trialJohn Marsden, Camille Goetz, Tim Meynen, et al.
Ebiomedicine|February 27, 2018
Memory-Focused Cognitive Therapy for Cocaine Use Disorder: Theory, Procedures and Preliminary Evidence From an External Pilot Randomised Controlled TrialJohn Marsden, Camille Goetz, Tim Meynen, et al.
Addiction (Abingdon, England)|January 31, 2025
Psychedelic-assisted treatment for substance use disorder: A narrative systematic reviewTheodore Piper, Francesca Small, Sam Brown, et al.
BMJ Open|October 21, 2022
Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluationNatalie Lowry, Fiona Cowden, Edward Day, et al.
BMJ Open|March 21, 2023
Patients' perceptions of self-administered dosing to opioid agonist treatment and other changes during the COVID-19 pandemic: a qualitative studyGemma Scott, Sophie Turner, Natalie Lowry, et al.
The Lancet. Psychiatry|April 7, 2019
Efficacy and cost-effectiveness of an adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: a pragmatic, open-label, randomised controlled trialJohn Marsden, Garry Stillwell, Kirsty James, et al.
Pageof 4